GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Revance Therapeutics
Revance is a biopharmaceutical company that produces a neurotoxin (a Botox analogue). Its stock price reflects its direct competition with the giant AbbVie (owner of Botox). The chart tells the story of the battle for share in the vast aesthetic medicine market.
Share prices of companies in the market segment - Pharma skin
Revance Therapeutics is an aesthetic biotech company known for its DAXXIFY, a long-acting Botox alternative, and other products. We've categorized it as a Pharmaceutical: Skin company. The chart below shows how investors view the rapidly growing aesthetic medicine market.
Broad Market Index - GURU.Markets
Revance Therapeutics is an aesthetic biotech company known for its DAXXIFY, a long-acting Botox alternative, and other products. As a market leader, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it to Revance's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
RVNC - Daily change in the company's share price Revance Therapeutics
For Revance Therapeutics, Inc., an aesthetic medicine company, daily volatility reflects its sensitivity to sales of its Botox analogue. This metric is an indicator of competition in the neurotoxin market.
Daily change in the price of a set of shares in a market segment - Pharma skin
Revance Therapeutics develops and markets neurotoxins (Botox analogs) for aesthetic and therapeutic use. The aesthetic medicine market is highly competitive. The chart below shows the average volatility in this sector, allowing you to assess how RVNC shares react to trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Revance is a biopharmaceutical company known for its Botox analogue and other aesthetic products. The company's stock price reflects demand for cosmetic procedures, which is driven by consumer confidence. Its share price reflects the contribution of innovative medicine to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Revance Therapeutics
Revance Therapeutics' year-over-year performance tells the story of its battle for market share in neurotoxins. Its market cap growth over the past 12 months reflects the commercialization of its drug, Daxxify, positioned as a longer-acting alternative to Botox. Its valuation is a bet on its ability to displace the market leader.
Annual dynamics of market capitalization of the market segment - Pharma skin
Revance is a biopharmaceutical company that directly competes with Botox through its product Daxxify. Its success depends on its ability to capture share in this vast aesthetic medicine market. The graph shows how its marketing efforts and innovation are driving its superior growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Revance, with its Botox analogue, tells the story of a daring newcomer challenging a monopolist with its dynamic approach. Its ability to outpace the market is a test of whether it can wrest market share from giant AbbVie through marketing and innovation. It's a classic story of competitive struggle.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Revance Therapeutics
Revance is an aesthetics company with a commercial product that competes with Botox. Its monthly performance is driven by the commercial success of its Daxxify product. Quarterly reports on sales growth and market share are key indicators.
Monthly dynamics of market capitalization of the market segment - Pharma skin
Revance Therapeutics is a biotech company that produces and markets botulinum toxin-based injectables for aesthetic and therapeutic purposes, competing with Botox. The graph below shows the overall dynamics of the skin pharmaceutical sector, a large and rapidly growing market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks in the aesthetics sector are a hybrid of defensive healthcare and cyclical luxury. The chart below shows the overall sentiment. What's more influential on Revance Therapeutics: stable demand for procedures or the general consumer inclination to save money?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Revance Therapeutics
The weekly performance of Revance, a biopharmaceutical company, reflects competition in the botulinum toxin market. Its stock price responds to sales of its Botox analogue and progress in the development of other aesthetic and therapeutic drugs.
Weekly dynamics of market capitalization of the market segment - Pharma skin
Revance Therapeutics develops neurotoxins (Botox analogs) for aesthetic and therapeutic applications. The chart shows how its weekly performance compares to the sector, reflecting its struggle for market share in the highly competitive aesthetic medicine market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Revance is a biopharmaceutical company operating in the aesthetic medicine field (similar to Botox). This business depends on consumer spending on beauty. The chart below shows how Revance shares, as a cyclical company, react to overall market expectations for the economy.
Market capitalization of the company, segment and market as a whole
RVNC - Market capitalization of the company Revance Therapeutics
Revance's market capitalization chart tells the story of a biotech company challenging the leader, Allergan (the maker of Botox), with its new neuromodulator. Its dynamics tell the story of the long battle for FDA approval and the beginning of commercial competition in the vast aesthetic medicine market.
RVNC - Share of the company's market capitalization Revance Therapeutics within the market segment - Pharma skin
Revance Therapeutics specializes in aesthetic and therapeutic medicine, competing with Botox. Its growing market share reflects the commercial success of its products. The chart below shows how investors assess its chances of capturing the market from the established leader.
Market capitalization of the market segment - Pharma skin
Revance Therapeutics is a biopharmaceutical company that produces injectables for aesthetic and therapeutic medicine, directly competing with Botox. The chart below shows the market capitalization of this rapidly growing sector. Its dynamics reflect the enormous demand for aesthetic procedures.
Market capitalization of all companies included in a broad market index - GURU.Markets
Revance Therapeutics is a company that produces botulinum toxin-based aesthetic and therapeutic products, a competitor to Botox. Its market capitalization reflects the vast and growing aesthetic medicine market. Its performance on the overall chart tells the story of how science is helping people look younger.
Book value capitalization of the company, segment and market as a whole
RVNC - Book value capitalization of the company Revance Therapeutics
Revance's book value is its capital and production capacity for producing an innovative neurotoxin (a Botox analog) with a longer-lasting effect. This is real, science-intensive capital aimed at capturing a share of the vast aesthetic medicine market. How has this asset changed? The chart below shows its dynamics.
RVNC - Share of the company's book capitalization Revance Therapeutics within the market segment - Pharma skin
Revance Therapeutics produces injectables for aesthetic and therapeutic medicine, including a Botox analogue. The chart shows the proportion of its advanced manufacturing capacity, reflecting the physical foundation upon which its innovative products are created.
Market segment balance sheet capitalization - Pharma skin
Revance, a biopharmaceutical company specializing in aesthetics, is a capital-intensive business. This requires R&D and manufacturing capabilities for its drugs. The BCap_Seg chart for the biotech sector shows that commercial success requires a substantial financial base.
Book value of all companies included in the broad market index - GURU.Markets
Revance's balance sheet includes its production facilities for the next-generation botulinum toxin (Daxxify) and a line of dermal fillers. The company's assets include its scientific platform and manufacturing base. The chart allows us to assess the material weight of this new, serious player in the aesthetic medicine market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Revance Therapeutics
Revance Therapeutics produces aesthetic and therapeutic products, including a Botox competitor. Its balance sheet consists of R&D and manufacturing capabilities. Its market capitalization reflects expectations for its ability to capture a share of the multibillion-dollar injectable cosmetics market.
Market to book capitalization ratio in a market segment - Pharma skin
Revance Therapeutics produces injectable neurotoxins for aesthetic medicine, directly competing with the renowned Botox. Its market valuation on the chart reflects its potential to capture a significant share of this vast and lucrative market.
Market to book capitalization ratio for the market as a whole
Revance Therapeutics develops products for aesthetic medicine. The company's value is determined by its brand (a Botox competitor) and patents. This chart shows the premium the market is willing to pay for strong brands and innovations in the fast-growing consumer healthcare sector.
Debts of the company, segment and market as a whole
RVNC - Company debts Revance Therapeutics
Revance Therapeutics, a biopharmaceutical company producing a neurotoxin (a Botox analog), is using significant debt to commercialize its product and compete with the giant AbbVie. This chart shows how the company is funding its ambitious entry into the vast aesthetic and therapeutic medicine market, which requires massive marketing expenditures.
Market segment debts - Pharma skin
Revance Therapeutics is a biotech company producing neurotoxins (Botox analogs) for aesthetic and therapeutic purposes. Competing in this market requires massive investments in marketing and clinical research. This chart shows how the company manages its significant debt to compete for market share with giant AbbVie (Allergan).
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Revance Therapeutics
Revance Therapeutics is a biopharmaceutical company operating in the aesthetic and therapeutic medicine market, whose main product is a Botox analogue. This chart shows how the company is using leverage to aggressively market and compete with giant AbbVie (Botox), reflecting its ambitious but risky strategy.
Market segment debt to market segment book capitalization - Pharma skin
Revance Therapeutics develops and markets botulinum toxin-based aesthetic and therapeutic products, directly competing with Botox. This is a huge and lucrative market. The chart shows debt trends in the sector, which helps assess how aggressively Revance is investing in marketing and R&D to capture market share from the leader.
Debt to book value of all companies in the market
Revance Therapeutics, a biopharmaceutical company in the aesthetic medicine sector, competes with major players in the market, requiring significant investments in R&D and marketing. This chart shows the overall debt burden in the market. It helps assess how aggressively the company is using capital to capture market share and how this impacts its debt burden.
P/E of the company, segment and market as a whole
P/E - Revance Therapeutics
Revance Therapeutics is a biotech company specializing in aesthetic and therapeutic medicine, best known for its Botox competitor. This chart shows the market sentiment for its flagship product. The dynamics reflect the success of its launch, competition with the industry leader, and potential for therapeutic applications.
P/E of the market segment - Pharma skin
Aesthetic medicine, where Revance competes with Botox, is a huge market. This chart shows the average valuation for pharmaceutical and cosmetic companies. It helps to understand that Revance is valued based on the potential of its drug, Daxxify, to take market share from Allergan due to its longer duration of action.
P/E of the market as a whole
Revance Therapeutics is a biopharmaceutical company operating in the aesthetic medicine field. Its main product is a neurotoxin, a competitor to Botox. The company's valuation depends on its ability to capture market share. This overall sentiment chart is important because aesthetic procedures are discretionary expenses, but for Revance, competitive advantage is paramount.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Revance Therapeutics
For Revance Therapeutics, Inc., a biopharmaceutical company producing injectables for aesthetic and therapeutic medicine, this chart illustrates market expectations for future sales. It reflects forecasts for its ability to compete with Botox and other established brands in the neurotoxin market.
%20P%2FE%20Revance%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Revance-Therapeutics&v=1772513880645 "Chart of the company's future (projected) P/E Revance Therapeutics")
Future (projected) P/E of the market segment - Pharma skin
Revance Therapeutics is a biotech company specializing in aesthetic and therapeutic medicine. Its flagship product, Daxxify, is a new neuromodulator (a Botox analog) with a longer-acting effect. The chart shows forecasts for the pharmaceutical industry, helping to assess how the market perceives Revance's ability to compete with the dominant Botox brand.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-skin&v=1772513880665 "Future (projected) P/E graph of the market segment - Pharma skin")
Future (projected) P/E of the market as a whole
Revance Therapeutics, Inc. is a biopharmaceutical company that produces a neurotoxin (a Botox analog) for aesthetic and therapeutic purposes. The company competes with the cosmetics giant AbbVie. This graph of overall consumer sentiment shows how much people are willing to spend on beauty treatments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513880684 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Revance Therapeutics
Revance Therapeutics is a biotech company producing neuromodulators (Botox analogs) for aesthetic and therapeutic purposes. The company's profits depend on the successful launch of its products and competition with the giant AbbVie (owner of Botox). This chart shows the battle for share in the multi-billion dollar aesthetic medicine market.
Profit of companies in the market segment - Pharma skin
Revance Therapeutics is a biotech company specializing in aesthetic and therapeutic medicine. This graph, which shows sector profitability, demonstrates the size of the aesthetic treatment market. Their drug, Daxxify, competes with Botox, offering longer-lasting results, potentially changing the game in the neurotoxin market.
Overall market profit
Revance Therapeutics is a biotech company specializing in aesthetic and therapeutic medicine. Its main product is a long-acting neurotoxin (similar to Botox). The aesthetics market is highly dependent on discretionary spending. When the economy and incomes are growing, as in this graph, people spend more on cosmetic procedures.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Revance Therapeutics
Revance Therapeutics is a biotech company that produces injectables for aesthetic and therapeutic medicine, including its own neurotoxin, Daxxify, a Botox competitor. This chart reflects analysts' expectations for capturing a share of the multi-billion dollar aesthetic treatment market and expanding its therapeutic indications.
%20profit%20of%20the%20company%20Revance%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Revance-Therapeutics&v=1772513880728 "Graph of future (projected) profit of the company Revance Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma skin
Revance Therapeutics is a biotech company producing and commercializing a neuromodulator (a Botox analog) for aesthetic and therapeutic purposes. Growth depends on the success of its product in a competitive market. This chart for the pharmaceutical sector shows general growth expectations for the aesthetic medicine market, a key market for Revance.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-skin&v=1772513880746 "Graph of future (predicted) profits of companies in a market segment - Pharma skin")
Future (predicted) profit of the market as a whole
Revance Therapeutics develops and markets aesthetic and therapeutic products, including a Botox analogue. Demand for aesthetic procedures is highly dependent on discretionary spending. This graph, reflecting profit expectations, is an indicator of consumer confidence and willingness to spend on beauty.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513880762 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Revance Therapeutics
Revance Therapeutics is a biotech company specializing in aesthetic and therapeutic medicine, known for its neurotoxin (a Botox analog). The chart shows how investors value its revenue. It reflects its ability to compete in the vast aesthetic medicine market and the potential of its products in therapeutic areas.
P/S market segment - Pharma skin
Revance Therapeutics specializes in aesthetic and therapeutic medicine, offering an innovative neurotoxin that competes with Botox. The company's revenue depends on the successful launch of this product. This chart shows the average valuation in the sector, helping to understand how investors view Revance's potential in the vast aesthetic medicine market.
P/S of the market as a whole
Revance Therapeutics is a biotech company that develops and markets aesthetic and therapeutic drugs, including its own neuromodulator (a Botox analog). This chart, showing the average market revenue estimate, helps understand how investors value the company, which is challenging the leader in the multibillion-dollar aesthetic medicine market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Revance Therapeutics
Revance Therapeutics is a biotech company specializing in aesthetic and therapeutic medicine. Its key product is daxibotulinumtoxinA, a long-acting Botox analogue. This chart shows how investors estimate the future market share of this drug in both cosmetology and the treatment of neurological disorders.
%20P%2FS%20Revance%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Revance-Therapeutics&v=1772513880811 "The graph of the company's future (projected) P/S Revance Therapeutics")
Future (projected) P/S of the market segment - Pharma skin
Revance Therapeutics, Inc. is a biotechnology company specializing in the development and commercialization of neurotoxins for aesthetic and therapeutic applications, including Daxxify, a Botox competitor. This chart shows the average estimated future sales in the aesthetic medicine sector. It helps understand how the market views Revance's potential in this market.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20skin&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-skin&v=1772513880822 "Future (projected) P/S market segment graph - Pharma skin")
Future (projected) P/S of the market as a whole
Revance Therapeutics is a biotechnology company specializing in the development and commercialization of neurotoxins (Botox analogs) for aesthetic and therapeutic purposes. This chart demonstrates the market's collective expectations for future revenue. The company's success in the highly competitive aesthetic medicine market is an indicator of consumer spending on beauty.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513880877 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Revance Therapeutics
This chart illustrates the sales of Revance Therapeutics, a biopharmaceutical company whose flagship product, DAXXIFY, is an injectable treatment for aesthetic wrinkle correction and a competitor to Botox. Revenue is generated from sales of this and other products. The trend demonstrates its market penetration and success in aesthetic medicine.
Sales of companies in the market segment - Pharma skin
Revance Therapeutics is a biotech company specializing in aesthetic and therapeutic medicine, specifically the development of neurotoxins (Botox analogs). This graph shows the growth of the aesthetic medicine market. Revance's innovative products, offering longer-lasting results, directly compete with the leaders and drive growth in this multi-billion dollar market.
Overall market sales
Revance Therapeutics is a biotech company producing neurotoxins (Botox analogs) for aesthetic and therapeutic purposes. Demand for its aesthetic products is highly dependent on discretionary spending. This graph of total revenue reflects consumers' willingness to spend on cosmetic procedures.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Revance Therapeutics
Revance Therapeutics produces and markets an injectable neuromodulator that competes with Botox. Future revenue depends on its success in the vast aesthetic medicine market and in therapeutic applications. The chart shows the forecast for this rapidly growing sector.
%20sales%20of%20the%20company%20Revance%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Revance-Therapeutics&v=1772513880963 "Schedule of future (projected) sales of the company Revance Therapeutics")
Future (projected) sales of companies in the market segment - Pharma skin
Revance Therapeutics is a biotech company operating in the aesthetic and therapeutic medicine market. Its flagship product is a next-generation injectable neuromodulator, a competitor to Botox. This chart shows the forecast for the entire aesthetic medicine market, which is showing steady growth driven by demographic trends.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-skin&v=1772513880971 "Schedule of future (projected) sales of companies in the market segment - Pharma skin")
Future (projected) sales of the market as a whole
Revance Therapeutics is a biotech company specializing in aesthetic and therapeutic medicine, known for its neurotoxin (a Botox analog). Demand for aesthetic procedures is highly dependent on discretionary spending. This graph, reflecting consumer confidence, is an indicator of people's willingness to spend money on cosmetic injections.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513881001 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Revance Therapeutics
Revance Therapeutics is a biotech company that produces injectables for aesthetic and therapeutic medicine, including a Botox analogue. The company's profitability depends on successfully competing in the vast aesthetic treatment market. This chart illustrates the balance between high marketing costs and the potentially high profits from selling popular "beauty injections."
Market segment marginality - Pharma skin
Revance Therapeutics is a biotech company specializing in aesthetic and therapeutic medicine, best known for its Botox competitor, Daxxify. Profitability depends on the successful launch and commercialization of their innovative neurotoxins. This chart shows their operating results in the highly competitive aesthetics market.
Market marginality as a whole
Revance Therapeutics is a biotech company that produces injectables for aesthetic and therapeutic medicine, including its own neuromodulator (similar to Botox). This overall profitability curve is important to them. Spending on aesthetic procedures is directly dependent on discretionary income and consumer confidence, which rise alongside the economy.
Employees in the company, segment and market as a whole
Number of employees in the company Revance Therapeutics
Revance Therapeutics is an aesthetic biotech company competing in the botulinum toxin market. As it launches its products, its commercial team is growing significantly. This graph clearly indicates its transformation from an R&D company to a full-fledged commercial player.
Share of the company's employees Revance Therapeutics within the market segment - Pharma skin
Revance Therapeutics is a biotech company operating in the aesthetic and therapeutic medicine market. This chart reflects its successful market launch. It shows the size of its large commercial team promoting its innovative neuromodulator (a Botox competitor), as well as the R&D team developing new products.
Number of employees in the market segment - Pharma skin
Revance Therapeutics, Inc. is a biotechnology company specializing in the development and commercialization of neuromodulators for aesthetic and therapeutic applications. This chart shows employment trends in the aesthetic medicine sector. The growth in marketing and sales positions reflects the launch of a new botulinum toxin, which competes with established brands.
Number of employees in the market as a whole
Revance Therapeutics develops aesthetic and therapeutic products, including a Botox competitor. Demand for aesthetic procedures is highly dependent on consumer spending. This employment rate chart is a barometer of financial confidence. With a stable income, people are more willing to spend on cosmetic procedures to enhance their appearance.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Revance Therapeutics (RVNC)
Revance Therapeutics is a biotech company producing aesthetic and therapeutic drugs, including a Botox competitor (DaxibotulinumtoxinA). It is a hybrid of R&D and commercial operations. The chart shows how the market values their patents and their ability to compete in the market. The high cost per employee reflects both the value of R&D and the high margins of injectables.
%20of%20the%20company%20Revance%20Therapeutics%20(RVNC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Revance-Therapeutics-RVNC&v=1772513881247 "Chart of market capitalization per employee (in thousands of dollars) of the company Revance Therapeutics (RVNC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma skin
Revance Therapeutics is a biotech company developing and commercializing aesthetic and therapeutic drugs, including a Botox competitor. Its value is based on its scientific developments and commercial potential. This chart shows the high market valuation of its product portfolio per employee.
%20by%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-skin&v=1772513881255 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma skin")
Market capitalization per employee (in thousands of dollars) for the overall market
Revance Therapeutics is a biotech company producing longer-acting neurotoxins (Botox analogs). The chart shows its valuation in the aesthetic medicine industry. The high market capitalization per employee reflects the enormous potential of their product, which could capture a significant share of the multi-billion dollar market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513881270 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Revance Therapeutics (RVNC)
Revance Therapeutics is an aesthetic medicine company and a direct competitor to AbbVie (Botox). Their key product is Daxxify, a neuromodulatory injection with, they claim, a longer-lasting effect. This chart illustrates their commercial struggle: profit per employee (primarily their expensive R&D and sales teams) depends on their ability to "win" market share from Botox.
%20Chart%20Revance%20Therapeutics%20(RVNC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Revance-Therapeutics-RVNC&v=1772513881280 "Company Profit Per Employee (in thousands of dollars) Chart Revance Therapeutics (RVNC)")
Profit per employee (in thousands of dollars) in the market segment - Pharma skin
Revance Therapeutics is a biopharmaceutical company that produces Daxxify, a long-acting neuromodulator (similar to Botox). This is a highly competitive market in aesthetic medicine. This metric reflects how successfully their sales team can capture market share from the leader.
%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-skin&v=1772513881370 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma skin")
Profit per employee (in thousands of dollars) for the market as a whole
Revance Therapeutics (RVNC) is a biopharmaceutical company that produces a neurotoxin (Daxxify), a competitor to Botox. It's an R&D and commercial business. This chart shows how well their expensive R&D machine (losses per employee) is offset by sales of the new drug in the highly competitive aesthetics niche.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513881387 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Revance Therapeutics (RVNC)
Revance Therapeutics is a biotech company producing neurotoxins (Botox analogs) for aesthetic and therapeutic purposes. This chart demonstrates the commercial success of its products. The growth in revenue per employee demonstrates its successful competition in the aesthetic medicine market and the effectiveness of its sales team in working with clinics.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Revance-Therapeutics-RVNC&v=1772513881391 "Sales chart per company employee Revance Therapeutics (RVNC)")
Sales per employee in the market segment - Pharma skin
Revance Therapeutics (RVNC) is entering the highly competitive aesthetic medicine market. Their product, Daxxify, is a new neuromodulator (a Botox competitor), and they also have a line of RHA fillers. This graph shows how much revenue each employee (especially their sales team) generates from these products. This measures their commercial success.
Sales per employee for the market as a whole
Revance Therapeutics (RVNC) is a biotech company that produces Daxxify, a Botox competitor. The company also has a line of fillers. This is the aesthetic market. This chart shows how effectively the company's expensive sales team is promoting the new drug to dermatologists and cosmetologists, competing with the giant AbbVie (Botox).
Short shares by company, segment and market as a whole
Shares shorted by company Revance Therapeutics (RVNC)
Revance Therapeutics is the maker of Daxxify, a new injectable anti-wrinkle treatment marketed as a "longer-lasting" competitor to Botox. The bearish sentiment shown by this chart is a bet that Revance will fail to displace Botox from its dominant position in the aesthetic medicine market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Revance-Therapeutics-RVNC&v=1772513881466 "Short Shares Chart for the Company Revance Therapeutics (RVNC)")
Shares shorted by market segment - Pharma skin
This chart measures investor pessimism in the aesthetic pharmaceutical sector, best known for botulinum toxins. Revance Therapeutics is a direct competitor to Botox. When investors short this segment, they anticipate price wars, market saturation, or a decline in consumer spending on beauty treatments, which directly impacts Revance's revenue.
Shares shorted by the overall market
Revance is a biotech company producing "aesthetics" (a competitor to Botox). It's pure luxury. This chart shows the rise in general fear. When investors fear a recession, they expect consumers to cut back on "beauty injections" and other non-essential cosmetic procedures first, which would hurt Revance.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Revance Therapeutics (RVNC)
Revance Therapeutics (RVNC) is the maker of DaxibotulinumtoxinA (Daxxify), a direct competitor to the renowned Botox. It's an aesthetic biotech. This indicator tracks how investors assess its chances of snatching market share from AbbVie, showing "overbought" (above 70) for strong sales or "oversold" (below 30) for a slow start.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Revance-Therapeutics-RVNC&v=1772513881547 "RSI 14 indicator chart for the company's stock Revance Therapeutics (RVNC)")
RSI 14 Market Segment - Pharma skin
Revance Therapeutics is a biotech company focused on aesthetics. Their key product, Daxxify, is a long-term Botox competitor and a wrinkle-smoothing neurotoxin. This chart reflects the overall sentiment in the biotech sector, helping to gauge the overall market sentiment toward this speculative industry.
RSI 14 for the overall market
Revance (RVNC), the maker of Botox, sees the "wealth effect" in this chart. In times of euphoria, consumers are eager to spend on cosmetics. During panic and recession, when savings are needed, "non-essential" injections are the first to be cut, as they are pure luxury.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RVNC (Revance Therapeutics)
Revance (RVNC) is a biotech that challenged AbbVie with the launch of Daxxify, a long-acting injectable (botulinum toxin) that competes with Botox. This chart shows the average target price. It reflects analyst expectations for the commercial success of Daxxify's launch and its ability to capture market share in aesthetic medicine.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RVNC-Revance-Therapeutics&v=1772513881607 "A chart showing analyst consensus forecasts for the expected stock price. RVNC (Revance Therapeutics)")
The difference between the consensus estimate and the actual stock price RVNC (Revance Therapeutics)
Revance (RVNC) is an "aesthetic" challenger. The company has challenged giant AbbVie (Botox) with its "designer" neurotoxin (Daxxify), which promises to last longer. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this "Botox war."
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RVNC-Revance-Therapeutics&v=1772513881625 "A chart showing the difference between the consensus forecast and the actual stock price. RVNC (Revance Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma skin
Revance is the "new Botox." The company challenged AbbVie (Botox) by releasing its neuromodulator (DaxibotulinumtoxinA) for aesthetic medicine. This chart displays analysts' overall expectations for the *entire* "dermatological" pharmaceutical sector. It shows whether experts believe the "beauty injection" market will grow.
Analysts' consensus forecast for the overall market share price
Revance Therapeutics (RVNC) is "Botox" 2.0. They developed Daxxify, a long-acting botulinum toxin that competes with AbbVie's Botox in both cosmetics and medicine. This chart shows the general sentiment of experts. It reflects the extent to which analysts believe consumers will have "extra" money for "beauty injections."
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Revance Therapeutics
Revance is Botox 2.0. Their signature feature is Daxxify, a new botulinum toxin (a Botox competitor) that (they claim) lasts longer (6 months vs. 3-4). This chart is a summary of their commercial launch. It reflects their (slow) sales growth and their (very expensive) battle with Goliath (AbbVie/Allergan) for a share of the aesthetics market.
AKIMA Market Segment Index - Pharma skin
Revance Therapeutics (RVNC) is a skin and aesthetics company. They challenged Botox by creating Daxxify, a wrinkle injection that lasts longer (up to 6 months). This chart compares their composite index to the sector, showing how far their Botox competitor is ahead of the competition.
The AKIM Index for the overall market
Revance Therapeutics is a biotech company that developed Daxxify, a long-acting neurotoxin (a Botox competitor) for aesthetics and therapeutics. It is being acquired by Crown Laboratories. This chart, which reflects the market average, provides a macro backdrop. It helps assess how Revance, an aesthetics innovator, stacks up against broader economic trends.
